Impact Investors’s AbbVie ABBV Stock Holding History

Impact Investors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,184	Closed	-$274K	–	94
2025 Q3	$274K	Buy	+1,184	New	+$241K	0.18%	86

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Impact Investors's ABBV Position: Q4 2025 in Review

Impact Investors sold out of AbbVie (ABBV) in Q4 2025, closing a stake of 1,184 shares — an estimated $274K sold.

Impact Investors first reported a position in ABBV in Q3 2025 and held it in 1 quarter. The position peaked at $274K in Q3 2025. 4,158 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.

Impact Investors reported no remaining AbbVie position as of Q4 2025 after selling out during the quarter.
Impact Investors sold 1,184 AbbVie shares in Q4 2025, an estimated $274K.
Impact Investors first reported a position in AbbVie in Q3 2025 and held it in 1 quarter.
Impact Investors's AbbVie position peaked at $274K in Q3 2025.
4,158 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.

Based on Impact Investors's 13F filing for Q4 2025, filed 21 Jan 2026.